Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model-Reference-Cited by-同舟云学术

Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model

Published:2023-05-27 Issue:11-12 Volume:28 Page:1534-1545
ISSN:1360-8185
Container-title:Apoptosis
language:en
Short-container-title:Apoptosis

Author:

Ba Diandian,Li Hongzhe,Liu Rongrong,Zhang Ping,Tang Yongmin

Funder

the Zhejiang Medical and Health Science and Technology Plan Project

National Natural Science Foundation of China

Key Project from Science and Technology Department of Zhejiang Province

Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Biochemistry (medical),Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s10495-023-01853-1.pdf

Reference44 articles.

1. Curran KJ, Margossian SP, Kernan NA et al (2019) Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.Blood(. 26:2361–2368. https://doi.org/10.1182/blood.2019001641

2. Fry TJ, Shah NN, Orentas RJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med. 1:20–28. https://doi.org/10.1038/nm.4441

3. Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet(. 9967:517–528. https://doi.org/10.1016/s0140-6736(14)61403-3

4. Gardner R, Wu D, Cherian S et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.Blood(. 20:2406. https://doi.org/10.1182/blood-2015-08-665547

5. Majzner RG (2018) Mackall.Tumor Antigen escape from CAR T-cell Therapy.Cancer Discov. 10:1219–1226. https://doi.org/10.1158/2159-8290.CD-18-0442

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel safer CD19CAR with shRNA interference of IFN-γ can reduce multiple cytokine levels without significantly compromising its killing efficacy;Apoptosis;2023-12-19